Compare Alnylam Pharmaceuticals, Inc. (ALNY) vs EPR Properties (EPR) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Alnylam Pharmaceuticals, Inc. vs EPR Properties — how do they compare? Alnylam Pharmaceuticals, Inc. trades at $288 (market cap $39.89B), while EPR Properties trades at $59.75 (market cap $4.56B). The key difference: Alnylam Pharmaceuticals, Inc. is far larger — about 8.7× EPR Properties's market cap, and EPR Properties pays a 6.24% dividend while Alnylam Pharmaceuticals, Inc. pays none. Which is the better fit depends on your goals.
| ALNY | EPR | |
|---|---|---|
Market Cap | $39.89B | $4.56B |
Sector | Health | Real Estate |
52-Week High | $491.22 | $61.21 |
52-Week Low | $278.09 | $48.71 |
Enterprise Value | $38.15B | $7.62B |
Dividend Yield | — | 6.24% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
EPR Properties trades at $59.62, up 0.08% on the day, with a bullish technical signal from moving averages. The REIT shows strong profitability with a 39.93% net income margin and has beaten earnings estimates for three consecutive quarters. Recent news highlights a $315 million Six Flags acquisition and monthly dividends, reinforcing its experiential real estate focus.
Outlook remains positive with a consensus price target of $63.00, though risks include portfolio transition execution and sensitivity to consumer discretionary spending. The stock offers a 6%+ yield with solid coverage, appealing for income investors amid stable occupancy and growth initiatives.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam has five drugs on the market: Onpattro and Amvuttra for hATTR amyloidosis, Givlaari for acute hepatic porphyria, Oxlumo for primary hyperoxaluria type 1, and Leqvio for hypercholesterolemia.
Read more on ALNY →About EPR Properties
EPR Properties is a REIT specializing in experiential real estate, including movie theaters and leisure destinations like ski resorts and water parks across the US and Canada.
Read more on EPR →
